로딩 중…
지수 로딩 중…
CG Invites Co., Ltd.
083790· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,030+0.59%
2026-06-19
Price Chart
CG Invites Co., Ltd.-43.50%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 79.20B KRW |
| Revenue | 28.60B KRW |
| Net Income | -12.96B KRW |
| Total Assets | 216.86B KRW |
| Net Assets | 112.84B KRW |
| Employees | 80 |
| Value | |
| P/B | 0.70x |
| P/S | 2.77x |
| FCF Yield | -25.36% |
| Profitability | |
| ROE | -11.49% |
| ROA | -5.98% |
| Op. Margin | -86.30% |
| Revenue Growth | 39.21% |
| Financial Health | |
| Debt Ratio | 192.18% |
| Total Debt | 43.79B KRW |
| FCF | -20.08B KRW |
| Cash | 8.98B KRW |
| Current Ratio | 0.46x |
| Performance | |
| 1Y Return | -43.50% |
| 1M Return | -8.04% |
| From 52W High | -48.88% |
| 1Y MDD | -62.82% |
| Trading | |
| Volume | 147,882 shares |
| Foreign Own. | 2.57% |
| Per Share | |
| EPS | -35 KRW |
| BPS | 1,096 KRW |
Company Info
CG Invites, established in 2000, changed its name in 2023 and was listed on KOSDAQ in 2006. The bio company specializes in digital genome new drug development, Printed Circuit Board/hot pack manufacturing, and healthcare solutions. It commercialized the anti-inflammatory analgesic 'Acellex' as South Korea's first new drug and is conducting US FDA clinical trials for molecular targeted anti-cancer drugs. CG Invites is establishing a healthcare platform that merges genome analysis with artificial intelligence and big data, aiming to become a leading company in the genome industry. The company is headquartered in Gangseo-gu, Seoul.